TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of additional antiemetic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of episodes of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity and activity of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intestinal metaplasia resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sleep disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive function (Iowa Gambling Task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative VASr scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRU value at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent platelet inhibition at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter‐patient variability of PRU values at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physical function improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FEV1 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak-flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cromoglycate prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Three-month survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Favorable functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tests in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin Excretion Rate (AER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean duration of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of need for antipyretics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Hemostasis (TTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Arterial Access (TTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Device Engagement (TTDe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: improved physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better psychological functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response to high-dose direct buprenorphine/naloxone induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hannover function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Weeks of adherence to exercise prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-h concentrations of AEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative nalbuphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological stability of NICU infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective peak physical activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Best spectacle-corrected visual acuity of 6/60 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of PCP
Endpoint domain: Mortality/survival
Primary endpoint: likelihood of being PCP-free
Endpoint domain: Mortality/survival
Primary endpoint: Gait speed increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean serum 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic bioavailability of R-(+)[2-13C]equol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional absorption of R-(+)[2-13C]equol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life of equol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during step-downs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during stair ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral rebound probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Viral failure probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CD4 cell percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: final root length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: root length increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression to class IV heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean survival time until progression
Endpoint domain: Mortality/survival
Primary endpoint: Total mortality due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IL-1β serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in IL-6 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: excessive daytime sleepiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement (>20% reduction in PANSS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rates (42% risperidone vs 55% haloperidol)
Endpoint domain: Mortality/survival
Primary endpoint: Symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: subjective anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of musical performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: performance confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in sulcus bleeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in relative clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Target lesion revascularisation (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Improvement of liver fibrosis indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: SDS-15 score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical screening participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TnT concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptoms of opioid withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective signs of opioid withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory markers (Interleukin-6, Interleukin-10, Triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ≥50% reduction in mean pain scores at week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥30% reduction in mean pain scores at week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac events at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ischemia-driven target lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Esophageal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diabetic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fluoroscopy time for needle access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use rating for laser DARRT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of death or Q-wave myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: maximum flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum detrusor pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved physical health after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved mental health after 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: recurrence rate of febrile seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Adherence to CONSORT-A checklist
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Morbidity of Hypertensive Disorders of Pregnancy (HDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of SPT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of peanut allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral activation in WM-related neural networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in AntiHSP27, 70 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fetal death induction rate
Endpoint domain: Mortality/survival
Primary endpoint: Return to normal diet
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Healing time of tonsillar fossae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faster onset in motor response to L-dopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in 'on phase' peak dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: More 'on' periods during waking day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: H pylori positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of trauma-related guilt cognitions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Death from cardiac causes or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Atrial tachyarrhythmia-free survival rates off antiarrhythmic drugs
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent pericarditis incidence
Endpoint domain: Mortality/survival
Primary endpoint: Median flare-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Volume of allogeneic blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in FT+ group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SG+ group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates of prosthesis designs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of pain attacks and exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thickness of the pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: executive function performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: memory span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: memory for details
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to complete CS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to complete IK
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of errors on the IK task
Endpoint domain: Adverse events/effects
Primary endpoint: mean glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: At least 75% improvement in the PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of 0 or 1 on the physician's global assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Weight loss at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contractures prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: serum CXCL10 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular fractional shortening (LVFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: abdominal bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median progression-free time
Endpoint domain: Mortality/survival
Primary endpoint: Total blood loss (TBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin (Hb) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Regional brain activity modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normalized high-frequency component of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal GH secretory-burst mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma antioxidant activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial serum glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucagon-like peptide-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No bleeding after six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial suppression after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unfavorable outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orocaecal transit time (OCTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: practical examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final grades
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain reduction ≥50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful abortion rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects achieving total asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean morning peak flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: TDS (Tissue Doppler Systolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVEDV (Left Ventricular End-Diastolic Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVESV (Left Ventricular End-Systolic Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cancer-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: tumor recurrence
Endpoint domain: Mortality/survival
Primary endpoint: neonatal mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: infectious disease mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: decrease in bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of bleeding during hepatectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CVP difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Isoflurane average dosage per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR, PVR, RPP during hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Switching from calcium channel blockers to first-line agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian blood pressure rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with ASD
Endpoint domain: Adverse events/effects
Primary endpoint: Reoperation rate for treating ASD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: JOA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive score of Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Udvalg for Kliniske Undersogelser (UKU) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced prolactin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progression of myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial length increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatinine clearance (ClCr) decrease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cholinergic gastrointestinal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: GPE satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinically significant pancreatic fistulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Outcome of pill treatment compared to supportive care alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes